Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID). It is a metabolite of phenylbutazone.
It was withdrawn from markets worldwide in the mid-1980s due to bone marrow suppression and the risk of Stevens–Johnson syndrome.